Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Peter G. Rose, James J. Java, Mark A. Morgan, Angeles Alvarez-Secord, Joshua P. Kesterson, Frederick Stehman, David P. Warshal, William T. Creasman, Parviz Hanjani, Robert T. Morris, Larry J. Copeland

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule > 1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) and overall survival (OS). Methods Among the 550 patients enrolled on GOG-152, two-hundred-sixteen patients were randomly assigned following 3 cycles of cisplatin and paclitaxel to receive SCS. In 15 patients (7%) surgery was declined or contraindicated. In the remaining 201 patients the operative and pathology reports were utilized to classify their disease status at the beginning of SCS as; no gross disease/microscopically negative N = 40 (19.9%), no gross disease/microscopically positive N = 8 (4.0%), and gross disease N = 153 (76.1%). Results The median PFS for patients with no gross disease/microscopically negative was 16.1 months, no gross disease/microscopically positive was 13.5 months and for gross disease was 11.7 months, P = 0.002. The median OS for patients with no gross disease/microscopically negative was 51.5 months, no gross disease/microscopically positive was 42.6 months and for gross disease was 34.9 months, P = 0.018. Conclusion Although as previously reported SCS did not change PFS or OS, for those who underwent the procedure, their operative and pathologic findings were predictive of PFS and OS. Surgical/pathological residual disease is a biomarker of response to chemotherapy and predictive of PFS and OS.

Original languageEnglish (US)
Pages (from-to)511-515
Number of pages5
JournalGynecologic Oncology
Volume143
Issue number3
DOIs
StatePublished - 2016

Fingerprint

Ovarian Neoplasms
Disease-Free Survival
Survival
Operative Surgical Procedures
Residual Neoplasm
Biomarkers
Pathology
Drug Therapy

Keywords

  • Pathologic complete response
  • Secondary cytoreduction

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer : An NRG Oncology/Gynecologic Oncology Group study. / Rose, Peter G.; Java, James J.; Morgan, Mark A.; Alvarez-Secord, Angeles; Kesterson, Joshua P.; Stehman, Frederick; Warshal, David P.; Creasman, William T.; Hanjani, Parviz; Morris, Robert T.; Copeland, Larry J.

In: Gynecologic Oncology, Vol. 143, No. 3, 2016, p. 511-515.

Research output: Contribution to journalArticle

Rose, Peter G. ; Java, James J. ; Morgan, Mark A. ; Alvarez-Secord, Angeles ; Kesterson, Joshua P. ; Stehman, Frederick ; Warshal, David P. ; Creasman, William T. ; Hanjani, Parviz ; Morris, Robert T. ; Copeland, Larry J. / Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer : An NRG Oncology/Gynecologic Oncology Group study. In: Gynecologic Oncology. 2016 ; Vol. 143, No. 3. pp. 511-515.
@article{02d2e827e3d8486ead82227558526939,
title = "Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study",
abstract = "Purpose GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule > 1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) and overall survival (OS). Methods Among the 550 patients enrolled on GOG-152, two-hundred-sixteen patients were randomly assigned following 3 cycles of cisplatin and paclitaxel to receive SCS. In 15 patients (7{\%}) surgery was declined or contraindicated. In the remaining 201 patients the operative and pathology reports were utilized to classify their disease status at the beginning of SCS as; no gross disease/microscopically negative N = 40 (19.9{\%}), no gross disease/microscopically positive N = 8 (4.0{\%}), and gross disease N = 153 (76.1{\%}). Results The median PFS for patients with no gross disease/microscopically negative was 16.1 months, no gross disease/microscopically positive was 13.5 months and for gross disease was 11.7 months, P = 0.002. The median OS for patients with no gross disease/microscopically negative was 51.5 months, no gross disease/microscopically positive was 42.6 months and for gross disease was 34.9 months, P = 0.018. Conclusion Although as previously reported SCS did not change PFS or OS, for those who underwent the procedure, their operative and pathologic findings were predictive of PFS and OS. Surgical/pathological residual disease is a biomarker of response to chemotherapy and predictive of PFS and OS.",
keywords = "Pathologic complete response, Secondary cytoreduction",
author = "Rose, {Peter G.} and Java, {James J.} and Morgan, {Mark A.} and Angeles Alvarez-Secord and Kesterson, {Joshua P.} and Frederick Stehman and Warshal, {David P.} and Creasman, {William T.} and Parviz Hanjani and Morris, {Robert T.} and Copeland, {Larry J.}",
year = "2016",
doi = "10.1016/j.ygyno.2016.09.005",
language = "English (US)",
volume = "143",
pages = "511--515",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer

T2 - An NRG Oncology/Gynecologic Oncology Group study

AU - Rose, Peter G.

AU - Java, James J.

AU - Morgan, Mark A.

AU - Alvarez-Secord, Angeles

AU - Kesterson, Joshua P.

AU - Stehman, Frederick

AU - Warshal, David P.

AU - Creasman, William T.

AU - Hanjani, Parviz

AU - Morris, Robert T.

AU - Copeland, Larry J.

PY - 2016

Y1 - 2016

N2 - Purpose GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule > 1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) and overall survival (OS). Methods Among the 550 patients enrolled on GOG-152, two-hundred-sixteen patients were randomly assigned following 3 cycles of cisplatin and paclitaxel to receive SCS. In 15 patients (7%) surgery was declined or contraindicated. In the remaining 201 patients the operative and pathology reports were utilized to classify their disease status at the beginning of SCS as; no gross disease/microscopically negative N = 40 (19.9%), no gross disease/microscopically positive N = 8 (4.0%), and gross disease N = 153 (76.1%). Results The median PFS for patients with no gross disease/microscopically negative was 16.1 months, no gross disease/microscopically positive was 13.5 months and for gross disease was 11.7 months, P = 0.002. The median OS for patients with no gross disease/microscopically negative was 51.5 months, no gross disease/microscopically positive was 42.6 months and for gross disease was 34.9 months, P = 0.018. Conclusion Although as previously reported SCS did not change PFS or OS, for those who underwent the procedure, their operative and pathologic findings were predictive of PFS and OS. Surgical/pathological residual disease is a biomarker of response to chemotherapy and predictive of PFS and OS.

AB - Purpose GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule > 1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) and overall survival (OS). Methods Among the 550 patients enrolled on GOG-152, two-hundred-sixteen patients were randomly assigned following 3 cycles of cisplatin and paclitaxel to receive SCS. In 15 patients (7%) surgery was declined or contraindicated. In the remaining 201 patients the operative and pathology reports were utilized to classify their disease status at the beginning of SCS as; no gross disease/microscopically negative N = 40 (19.9%), no gross disease/microscopically positive N = 8 (4.0%), and gross disease N = 153 (76.1%). Results The median PFS for patients with no gross disease/microscopically negative was 16.1 months, no gross disease/microscopically positive was 13.5 months and for gross disease was 11.7 months, P = 0.002. The median OS for patients with no gross disease/microscopically negative was 51.5 months, no gross disease/microscopically positive was 42.6 months and for gross disease was 34.9 months, P = 0.018. Conclusion Although as previously reported SCS did not change PFS or OS, for those who underwent the procedure, their operative and pathologic findings were predictive of PFS and OS. Surgical/pathological residual disease is a biomarker of response to chemotherapy and predictive of PFS and OS.

KW - Pathologic complete response

KW - Secondary cytoreduction

UR - http://www.scopus.com/inward/record.url?scp=84997816015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997816015&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.09.005

DO - 10.1016/j.ygyno.2016.09.005

M3 - Article

C2 - 27692669

AN - SCOPUS:84997816015

VL - 143

SP - 511

EP - 515

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -